These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37221619)

  • 1. Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Hoffmann E; Gerwing M; Krähling T; Hansen U; Kronenberg K; Masthoff M; Geyer C; Höltke C; Wachsmuth L; Schinner R; Hoerr V; Heindel W; Karst U; Eisenblätter M; Maus B; Helfen A; Faber C; Wildgruber M
    Breast Cancer Res; 2023 May; 25(1):56. PubMed ID: 37221619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric MRI enables for differentiation of different degrees of malignancy in two murine models of breast cancer.
    Gerwing M; Hoffmann E; Kronenberg K; Hansen U; Masthoff M; Helfen A; Geyer C; Wachsmuth L; Höltke C; Maus B; Hoerr V; Krähling T; Hiddeßen L; Heindel W; Karst U; Kimm MA; Schinner R; Eisenblätter M; Faber C; Wildgruber M
    Front Oncol; 2022; 12():1000036. PubMed ID: 36408159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI.
    Hoffmann E; Gerwing M; Niland S; Niehoff R; Masthoff M; Geyer C; Wachsmuth L; Wilken E; Höltke C; Heindel WL; Hoerr V; Schinner R; Berger P; Vogl T; Eble JA; Maus B; Helfen A; Wildgruber M; Faber C
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
    Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
    Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized time-resolved imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models.
    Haeck J; Bol K; Bison S; van Tiel S; Koelewijn S; de Jong M; Veenland J; Bernsen M
    Contrast Media Mol Imaging; 2015; 10(6):413-20. PubMed ID: 25995102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
    Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
    Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
    Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.
    Chen BB; Shih TT
    World J Gastroenterol; 2014 Mar; 20(12):3125-34. PubMed ID: 24695624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
    Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
    Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
    Zheng X; Kuai J; Shen G
    Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent.
    Phinikaridou A; Andia ME; Passacquale G; Ferro A; Botnar RM
    J Am Heart Assoc; 2013 Sep; 2(5):e000402. PubMed ID: 24072533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
    Huuse EM; Moestue SA; Lindholm EM; Bathen TF; Nalwoga H; Krüger K; Bofin A; Maelandsmo GM; Akslen LA; Engebraaten O; Gribbestad IS
    J Magn Reson Imaging; 2012 May; 35(5):1098-107. PubMed ID: 22170753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
    Luo Y; Jiang F; Cole TB; Hradil VP; Reuter D; Chakravartty A; Albert DH; Davidsen SK; Cox BF; McKeegan EM; Fox GB
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):911-21. PubMed ID: 22080168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.
    Sunay MM; Foote JB; Leatherman JM; Edwards JP; Armstrong TD; Nirschl CJ; Hicks J; Emens LA
    Int Immunopharmacol; 2017 May; 46():112-123. PubMed ID: 28282575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.